Seoul, South Korea – Samsung Biologics, a leading contract development and manufacturing organization (CDMO), announced today that it has secured a groundbreaking $2 billion contract, the largest in its history since its establishment in 2011.

The company revealed this significant deal at the JP Morgan Healthcare Conference 2025, a premier global investment event for the pharmaceutical and biotechnology industries, currently underway in San Francisco. According to the official announcement, the contract is with a European pharmaceutical company, spanning a period until December 31, 2030. While the specific customer and product have been kept confidential due to non-disclosure agreements, the contract represents a substantial 40% of Samsung Biologics' total orders for the previous year.

Samsung Biologics has been demonstrating consistent growth in its order book. Annual orders have been increasing by around 1.5 times year-on-year, reaching ₩1.78 trillion in 2022, ₩3.5 trillion in 2023, and ₩5.4 trillion in 2024. Last year alone, the company closed three 'big deals' worth over ₩1 trillion. With this latest $2 billion contract, analysts predict even higher growth this year.

A company spokesperson emphasized, “We currently serve 17 of the top 20 global pharmaceutical companies. To proactively address the growing demand for biopharmaceuticals, we plan to commence operations at our 180,000-liter fifth plant in Songdo, Incheon, this April.” Upon the completion of the fifth plant, Samsung Biologics’ total production capacity will expand to 784,000 liters.

The company is actively engaging in global networking to further expand its business. The spokesperson added, “We are consistently participating in pharmaceutical and biotechnology conferences worldwide, including the US, Europe, and Asia. At this year’s JP Morgan Healthcare Conference, we are actively meeting with investors and potential clients to strengthen our network and drive business growth.”